, Thailand
/Pixabay

Muang Thai Life to see improved new business value growth: Fitch Ratings

MTL has witnessed a modest earnings recovery during the third quarter of 2023.

Fitch Ratings anticipates the improvement of the Muang Thai Life’s (MTL) new business value growth in the medium term, supported by robust demand for health-related products, protection, and riders in preparation for IFRS17, as well as enhanced market opportunities through its partnership with KBank and efficiency gains from digital transformation in distribution networks.

MTL has witnessed a modest earnings recovery, with an annualised return on equity rising to 6.8% in 3Q23, compared to below 6.5% in 9M22 (2021: 10.2%). Its three-year average return on equity over 2021-9M23 stands at 7.9%, within the range for its rating category. 

ALSO READ: Association predicts 2.0%-4.0% growth for Thai life insurance

Despite an increase in the allocation of fixed-income securities to 81% in 3Q23, up from 77% in 2021, MTL's overall risky asset ratio remained unchanged. 

The three-year average risky asset ratio stood at 241%, similar to 243% at 3Q23. This is attributed to a slight rise in the allocation to below-investment-grade bonds, which constituted 95% of capital in 3Q23, compared to 90% in 2021.

Follow the link s for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.